Shots:

• Sosei Heptares to receive $44M as upfront- near-term development milestones- and funding and is eligible to receive $437M as development- regulatory- and commercialization along with royalties on sales of products resulting from the collaboration
• GSK gets the global rights to a Sosie Heptares’ portfolio of GPR35 agonists- developed utilizing StaR technology & SBDD platform. The licensed portfolio includes an advanced lead preclinical compound as well as multiple differentiated back-up compounds
• The companies collaborated on research and early preclinical development while GSK will lead clinical development- manufacturing- and commercialization

 ­ Ref: PRNewswire | Image: GSK